OUR TEAM

We have assembled a team with deep scientific, clinical, manufacturing, business, and leadership expertise in biotechnology, platform research, discovery, development, and commercialization of new therapies.

Samuel Agresta, MD, MPH & TM

Chief Medical Officer

Samuel Agresta, MD, MPH & TM

Chief Medical Officer

Samuel Agresta, MD, MPH & TM, joined Foghorn Therapeutics in 2019 as chief medical officer. He brings over a decade of clinical development experience with global development and regulatory expertise in both solid and hematologic cancers.

Prior to joining Foghorn, Sam was the chief medical officer at Infinity Pharmaceuticals. During his career, Sam spent 8 years at Agios Pharmaceuticals, where he was responsible for the development and approvals of TIBSOVO® and IDHIFA® for patients with IDH1 and IDH2 mutation positive acute myeloid leukemia. Sam has also held positions at Merrimack and Genentech. While he was at Genentech, he played a role in the global development of KADCYLA®, which is approved for HER2 positive breast cancer. Sam was trained in medical oncology at the University of South Florida’s Moffitt Cancer Center and stayed on as an associate medical director in the Sarcoma Department.

Sam is a member of Infinity’s Board of Directors. He received his medical degree from Tulane University School of Medicine as well as a Master in Public Health from Tulane University School of Health and Tropical Medicine.

Steven Bellon, PhD

SVP, Drug Discovery

Steven Bellon, PhD

SVP, Drug Discovery

Steven Bellon, PhD, joined Foghorn Therapeutics in 2016 as head of drug discovery. He brings to the role more than 20 years of drug discovery experience from multiple target classes.

Before joining Foghorn, Steven was executive director and head of structural biology, and lead in discovery and project management at Constellation Pharmaceuticals. At Constellation, he built the structural biology group, built and co-led the bromodomain platform efforts in collaboration with Genentech, and was a member of the portfolio management committee. Steven has a passion for drugging novel targets and has contributed to many drug discovery efforts in oncology including those for p38, HCV helicase, cMet, BET, EZH2, and numerous bromodomains. Prior to his work at Constellation, he held positions of increasing responsibility at Amgen and Vertex Pharmaceuticals.

Steven received a PhD in physical chemistry from MIT under the direction of Stephen Lippard and then completed postdoctoral training at Yale University with Thomas Steitz, funded by a Damon Runyon fellowship.

Fanny Cavalié

SVP, Business & Operations

Fanny Cavalié

SVP, Business & Operations

In her role as senior vice president of business & operations, Fanny guides Foghorn Therapeutics’ business development, strategic planning, commercial development, communication and operations. She brings over 15 years of international healthcare experience across multiple disease areas and stages of drug development and commercialization.

Prior to joining the company, Fanny held various roles at Biogen, including head of multiple sclerosis portfolio strategy and head of launch excellence. Most recently, she was the global commercial development lead for Biogen’s neurodegeneration therapeutic area. In this role, she was responsible for the launch preparation for aducanumab in Alzheimer’s disease, market development, commercial alliances, and new product planning for multiple assets in preclinical and clinical stages.

Before joining Biogen, Fanny spent 10 years advising executive teams of international biopharmaceutical companies as an associate partner at McKinsey & Company in London, where she co-led the firm’s European pharmaceutical launch practice. During her time at McKinsey, Fanny led over 50 teams to support more than 10 drug launches, designed over 10 corporate, business development and product strategies, and supported multiple organizational designs and partnerships.

Fanny earned her master’s degree in business administration from HEC in France, where she graduated with high honors.

Jacqueline Cinicola

VP, Regulatory Affairs

Jacqueline Cinicola

VP, Regulatory Affairs

Jackie joined Foghorn as VP of regulatory affairs in July 2020. She has more than 30 years of pharmaceutical development experience, with a focus in clinical and global regulatory strategy.

Prior to joining Foghorn, Jackie was the senior director of regulatory affairs at Agios Pharmaceuticals. Over a period of 7 years at Agios Pharmaceuticals, Jackie built a strategic-focused regulatory team that was responsible for IND applications supporting 8 investigational products to treat hematologic malignancies, solid tumors and rare genetic diseases and for the approved marketing application for TIBSOVO®. Prior to Agios, she spent 10 years as an independent consultant providing regulatory support and strategic assessments to a variety of pharmaceutical companies. Preceding this, Jackie contributed to the initial build of regulatory and clinical teams at Millennium Pharmaceuticals, LeukoSite and Vertex Pharmaceuticals; she started her pharmaceutical career in the chemistry labs and then on the clinical team at the R.W. Johnson Pharmaceutical Research Institute. During her career, Jackie provided lead regulatory support for the approval of CAMPATH® and actively advanced the clinical development (IDHIFA®, VELCADE®, ENTYVIO®, LEVAQUIN®, FLOXACIN®).

Jackie earned a master’s degree in medicinal chemistry and a bachelor’s degree in pharmacy from Duquesne University.

Carlos Costa

SVP, People & Organization

Carlos Costa

SVP, People & Organization

Carlos brings over 20 years of experience in organizational and human capital management acquired from working in the biotech, pharma and consumer goods industries around the world.

Prior to joining the company, Carlos held various roles of increasing responsibility at Biogen, in multiple areas and geographies ranging from human resources business partner for Spain, Portugal, and Italy, to HR lead for global commercial functions in the United States and the Emerging Markets region. In his most recent role at Biogen, Carlos was the head of human resources for Europe, Canada, and International Partner Markets.

Before joining Biogen, Carlos spent 10 years serving as HR business partner in companies like Gillette and Roche, where he built teams, led transformations and served as strategic partner to the business.

Carlos holds a BS in law from UNED in Spain and received his human resources master’s degree from EADA in Barcelona. He also holds a PDD from IE Instituto de Empresa, Madrid and the Executive Leadership Program at Harvard Business School, Boston.

Carl P. Decicco, PhD

Chief Scientific Officer

Carl P. Decicco, PhD

Chief Scientific Officer

Carl P. Decicco, PhD, joined Foghorn Therapeutics in 2018 as chief scientific officer. He brings more than 30 years of biopharmaceutical and R&D experience to the company.

Prior to joining Foghorn, Carl spent 17 years at Bristol-Myers Squibb (BMS), where he most recently served as senior vice president, head of discovery since 2013 and was a member of the R&D leadership team. Carl first joined BMS as part of the DuPont Pharmaceuticals acquisition in 2001 as head of discovery chemistry. Over his career in biopharmaceutical research, Carl has played a central role in the advancement of more than 200 compounds into clinical trials and the approval of more than 20 drugs across multiple therapeutic areas in both small molecules and biologics.

Carl has authored or co-authored more than 100 scientific papers in peer reviewed journals, is listed as an inventor on 26 patents and has lectured extensively at major academic and Industrial institutions. Carl received his PhD in organic chemistry from the Guelph-Waterloo Center in Ontario, Canada. He completed his post-doctoral studies at Harvard University, and was a teaching fellow at the University of British Columbia. In 2018, Carl was the recipient of the Bloch Lectureship Award from the University of Chicago for his achievements and contributions to advancing science. He has served on numerous university boards and has joined Flagship Pioneering as a venture partner.

Adrian Gottschalk

President & CEO

Adrian Gottschalk

President & CEO

Adrian is president and chief executive officer of Foghorn Therapeutics. An experienced leader in biotech, Adrian is interested in solving complex issues at the intersection of science, medicine, and business on a global scale to help people and families dealing with diseases.

Prior to joining Foghorn, Adrian spent 13 years at Biogen, where he was most recently a senior vice president and the neurodegeneration therapeutic area head. In this role, he was responsible for the late-stage development and commercialization of medicines for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). During his time at Biogen, Adrian held additional roles of increasing responsibility ranging from head of corporate strategy, head of global commercial strategy, head of Japan, and head of the Japan, Australia and Emerging Markets geographies. He has also worked as a consultant for Price Waterhouse in Dallas, Texas.

He holds a BS in biochemistry from Texas A&M University and received his MBA from the Sloan School of Management at MIT. He also holds an ScM degree from the joint Harvard Medical School / MIT Biomedical Enterprise Program, where his graduate work was focused on evaluating the costs and benefits of the Prescription Drug User Fee Acts and improving the efficiency of the drug development process.

Chong-Hui Gu

VP, CMC and QA

Chong-Hui Gu

VP, CMC and QA

Chong-Hui Gu, PhD, is responsible for CMC, supply chain and quality assurance at Foghorn Therapeutics. He brings 20 years of drug discovery and development experiences in multiple disease areas.

Prior to joining Foghorn, Chong-Hui was VP, CMC and DHODH program leader at Agios Pharmaceuticals, where he led the CMC development of IDHIFA®, TIBSOVO®, mitapivat and vorasidenib. Prior to that, he held positions at Vertex Pharmaceuticals and Bristol-Myers Squibb, where he contributed to the formulation and CMC development of INCIVEK®, KALYDECO®, ORKAMBI® and ELIQUIS®.

Chong-Hui received a PhD in pharmaceutics from the University of Minnesota, Twin Cities, and a BS in pharmacy from Fudan University in China.

Murphy Hentemann, PhD

VP, Program Leadership

Murphy Hentemann, PhD

VP, Program Leadership

Murphy Hentemann, PhD, joined Foghorn in 2018 as head of program management, now VP, program leadership. He brings more than 18 years of drug discovery experience to the organization.

Before joining Foghorn, Murphy was a director of oncology program management at Novartis Institute for Biomedical Research. Prior to that, he held positions of increasing responsibility at AstraZeneca, Array Biopharma, and Bayer Healthcare, as a medicinal chemist and drug discovery program leader. Murphy has contributed to the discovery and early development of multiple clinical candidates in the oncology space, including leading the teams that discovered ALIQOPA™ and Ipatasertib.

Murphy received a PhD in organic chemistry from Purdue University under the direction of Philip Fuchs, and then completed postdoctoral training at Memorial Sloan Kettering under Samuel Danishefsky as an NIH Postdoctoral Fellow.

Scott Innis

VP, Program Leadership

Scott Innis

VP, Program Leadership

Scott joined Foghorn in 2018 to lead new product planning and guide a range of business operations initiatives. He currently serves as a vice president and program lead. Scott has over 15 years of experience in program, disease and portfolio strategy across multiple therapeutic categories and carries a passion for translating scientific advancement into new medicines.

Before joining Foghorn, Scott held a variety of strategic and operational roles across all phases of development within the multiple sclerosis and neurodegeneration therapeutic areas at Biogen. Prior to Biogen, Scott was a strategy consultant at Leerink Partners where he advised biopharmaceutical clients on program development, licensing, and therapeutic area strategy. He started his career at Altus Pharmaceuticals in corporate and commercial development.

Scott holds an MS in biotechnology from Northwestern University and a BS in zoology from Miami University (OH).

Ryan Kruger, PhD, VP, Biology
Ryan Kruger, PhD

VP, Biology

Ryan Kruger, PhD

VP, Biology

Ryan Kruger, PhD, joined Foghorn Therapeutics in March 2021 as VP of biology. He brings more than 16 years of experience in the field of epigenetics research.

Prior to joining Foghorn, Ryan was the VP, head of cancer epigenetics research at GlaxoSmithKline (GSK). In this position, he established the strategy for the Epigenetics unit that focused on identifying targets and progressing evidence-based candidates for their role in cancer with genetic/epigenetic biomarkers. Notably, Ryan also served as the early development leader for one of GSK’s compounds and led the clinical team in three tumor types from first-in-human trial through combination studies in the clinic.

Ryan received his bachelor’s degree in biochemistry from Rensselaer Polytechnic Institute and his PhD from the University of Pennsylvania. He completed his post-doctoral training with Christopher T. Walsh at Harvard Medical School. During his career, Ryan has authored or coauthored 48 publications and has received numerous awards and fellowships.

Michael LaCascia

Chief Legal Officer

Michael LaCascia

Chief Legal Officer

Michael LaCascia joined Foghorn Therapeutics in November 2020 as chief legal officer. He brings over 30 years of legal experience with broad corporate, securities, governance, and transactional expertise in the biotechnology industry.

Before joining Foghorn, Mike was the chief legal officer at Q-State Biosciences. As part of the executive leadership team, he worked to transition Q-State’s corporate strategy from providing enabling discovery services to the discovering of its proprietary therapeutics. Prior to that, Mike was the senior vice president, general counsel and secretary of Vertex Pharmaceuticals, where he led its global legal function, supported numerous business development initiatives, and enhanced corporate governance for the company as it witnessed substantial growth during several product approvals. Mike also served as an attorney for more than two decades at WilmerHale LLP (and its constituent firm, Hale and Dorr) where he was a partner in that firm’s corporate practice specializing in securities, mergers and acquisitions (M&A) and corporate governance matters.

In addition, Mike was an adjunct faculty instructor at Boston University School of Law for over a decade teaching Negotiated M&A to U.S. and international law students.

Mike received his Juris Doctor degree from Boston University and his Bachelor of Arts in economics from Harvard College.

Nicola Majchrzak

VP, Clinical Development Operations

Nicola Majchrzak

VP, Clinical Development Operations

Nicola joined Foghorn Therapeutics in 2019 as senior director of clinical development operations to build and lead a group tasked with advancing Foghorn’s assets into the clinic.

Before joining Foghorn, Nicola was project lead at Infinity Pharmaceuticals. Prior to her experience at Infinity, Nicola spent the bulk of her career in the care delivery space, creating and implementing new models of health care delivery that redesigned care at the frontline, payment models and IT systems to better meet the needs of patients, families and providers.

Nicola has deep experience growing and leading multidisciplinary, geographically distributed teams in matrixed organizations and in the healthcare start-up community. Nicola has contributed to the build of companies from the ground-up to multi-million-dollar enterprises, most notably Iora Health which has a national presence with more than 45 practices distributed across the US. At Iora, Nicola initially led operations and then talent and culture growth strategy and the physician group.

Nicola received her Master in Public Health and Master in Social Work from the University of Michigan, Ann Arbor.

David Millan, PhD

VP, Chemistry

David Millan, PhD

VP, Chemistry

David Millan, PhD, is the vice president of chemistry at Foghorn Therapeutics. Before joining the company, David was the head of medicinal chemistry at FORMA Therapeutics, where he helped build the medicinal chemistry group and led programs in epigenetics and metabolism through to IND.

Prior to this appointment, David held positions of increasing responsibility at Pfizer in the U.K., making significant contributions to the discovery of multiple clinical candidates in respiratory and pain therapeutics. David began his career at Vertex Pharmaceuticals in the U.K., working as a medicinal chemist.

David holds a BSc with honors (first class) and a PhD in chemistry from Flinders University, in Adelaide, Australia. He completed postdoctoral research at University of Nottingham, in the laboratory of Gerald Pattenden, working on the total synthesis of the complex marine natural product phorboxazole A.

Allan Reine, MD

Chief Financial Officer

Allan Reine, MD

Chief Financial Officer

Allan Reine, MD, joined Foghorn Therapeutics in 2019 as chief financial officer. He has more than 10 years of financial experience in the biotechnology and pharmaceuticals industry.

Prior to joining Foghorn, Allan was chief financial officer at Pieris Pharmaceuticals, Inc. Throughout his career, Allan has managed various healthcare portfolios focused on biotechnology and pharmaceutical companies at Lombard Odier Asset Management, Citi Principal Strategies, SAC Capital Advisors, Trivium Capital and Alexandra Investment Management. He started his career at CIBC World Markets where he worked in both biotechnology investment banking and biotechnology equity research.

Allan received his MD from the University of Toronto, and his Bachelor of Science in statistical sciences from the University of Western Ontario.

Ben Strain

VP, Investor Relations & Corporate Communications

Ben Strain

VP, Investor Relations & Corporate Communications

Ben Strain joined Foghorn Therapeutics in 2021 as vice president of investor relations and corporate communications. He brings over 20 years of experience and most recently led the investor relations and communications functions for Paratek Pharmaceuticals and Biogen, where he successfully guided the investor communication strategy for a diverse set of preclinical and clinical candidates and nine new product launches in four distinct therapeutic areas including neurology, infectious disease, hematology and rare disease.

Prior to his roles at Paratek and Biogen, Ben was an instrumental member of the investor relations function at Under Armour and held positions of increasing responsibility at The Boston Company Asset Management, a subsidiary of the Bank of New York Mellon, making significant contributions to several U.S. and ex-US based equity funds.

Ben holds an MBA from McCallum Graduate School of Business at Bentley University and a BS in economics from Peter T. Paul College of Business and Economics at the University of New Hampshire.

Scott Biller, PhD

Strategic Advisor, Agios Pharmaceuticals

Scott Biller, PhD

Strategic Advisor, Agios Pharmaceuticals

Scott Biller, PhD, is a strategic advisor to Agios Pharmaceuticals and served as the Company’s chief scientific officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates.

Scott has more than 30 years of drug discovery and development experience with notable positions at Novartis Pharmaceuticals and Bristol Myers Squibb.

During his career, Scott contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials.

Scott earned a BS in chemistry at MIT, a PhD in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.

Doug Cole, MD

Founder, Foghorn Therapeutics Managing Partner, Flagship Pioneering

Doug Cole, MD

Founder, Foghorn Therapeutics Managing Partner, Flagship Pioneering

An entrepreneur, investor, and physician, Doug Cole, MD plays an active role as a co-founder and initial CEO of multiple Flagship companies, including Foghorn Therapeutics. Doug has a significant track record of board experience and currently serves on the board of directors of numerous public and private companies.

Included among the companies Doug has helped build are Agios Pharmaceuticals (NASDAQ: AGIO), Denali Therapeutics (NASDAQ: DNLI), Editas Medicine (NASDAQ: EDIT), Hypnion (acquired by Eli Lilly), Morphotek (acquired by Eisai), Quanterix (NASDAQ: QTRX), Receptos (NASDAQ: RCPT; acquired by Celgene), and Syros Pharmaceuticals (NASDAQ: SYRS).

He is trained as a neurologist and completed his post-graduate training at the John Hopkins Hospital in Baltimore, MD, and the Massachusetts General Hospital, in Boston, MA. Prior to joining Flagship in 2001, Doug held medical posts at Harvard Medical School and the Massachusetts General Hospital, and he has also served as an executive at Cytotherapeutics and Vertex Pharmaceuticals.

Doug holds an AB magna cum laude with high distinction in English from Dartmouth College and an MD from University of Pennsylvania School of Medicine.

Simba Gill, PhD

President & CEO, Evelo Biosciences

Simba Gill, PhD

President & CEO, Evelo Biosciences

Simba Gill, PhD, is president and chief executive officer of Evelo Biosciences, a Flagship VentureLabs® company leading the development of monoclonal microbials, a new modality of medicine for the treatment of cancer and autoimmune and inflammatory diseases.

He is also a senior partner at Flagship Pioneering, where he provides strategic counsel and support to the firm’s portfolio companies. Prior to his roles at Evelo and Flagship, Simba was a partner at TPG, a major private equity investor, where he focused on global healthcare and biotech investments. He has also held leadership roles at Roche/Boehringer Manheim.

Simba has a long track record of identifying new technologies and geographies for high-growth business opportunities. He has founded and held leading roles in multiple pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, gene therapy, and immunodiagnostics. Four of these companies have gone public and three were acquired through strategic trade sales.

Simba holds his MBA from INSEAD and received his PhD from King’s College, London, where he focused on developing humanized antibodies to treat cancer in collaboration with Celltech.

Adrian Gottschalk

President & CEO

Adrian Gottschalk

President & CEO

Adrian is president and chief executive officer of Foghorn Therapeutics. An experienced leader in biotech, Adrian is interested in solving complex issues at the intersection of science, medicine, and business on a global scale to help people and families dealing with diseases.

Prior to joining Foghorn, Adrian spent 13 years at Biogen, where he was most recently a senior vice president and the neurodegeneration therapeutic area head. In this role, he was responsible for the late-stage development and commercialization of medicines for Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). During his time at Biogen, Adrian held additional roles of increasing responsibility ranging from head of corporate strategy, head of global commercial strategy, head of Japan, and head of the Japan, Australia and Emerging Markets geographies. He has also worked as a consultant for Price Waterhouse in Dallas, Texas.

He holds a BS in biochemistry from Texas A&M University and received his MBA from the Sloan School of Management at MIT. He also holds an ScM degree from the joint Harvard Medical School / MIT Biomedical Enterprise Program, where his graduate work was focused on evaluating the costs and benefits of the Prescription Drug User Fee Acts and improving the efficiency of the drug development process.

Cigall Kadoch, PhD

Founder, Foghorn Therapeutics Assistant Professor, Dana-Farber & Broad Institute

Cigall Kadoch, PhD

Founder, Foghorn Therapeutics Assistant Professor, Dana-Farber & Broad Institute

Cigall Kadoch, PhD, is an assistant professor of pediatric oncology at the Dana-Farber Cancer Institute, assistant professor of biological chemistry and molecular biology at Harvard Medical School, and Institute member and co-director of the epigenomics program at the Broad Institute of MIT and Harvard.

Cigall established her independent laboratory in 2014 at the age of 27, immediately following completion of her PhD studies in cancer biology at Stanford University. She is one of the youngest scientists ever appointed to the Harvard Medical School faculty. She has quickly become a leading expert in chromatin and gene regulation and is internationally recognized for her groundbreaking studies in these areas.

In addition to receiving numerous prestigious awards and research grants to support her academic laboratory at Harvard—including the NIH Director’s New Innovator Award, the Pew Scholar Award, and the American Cancer Society Research Scholar Award—Cigall was named to the Forbes 2014 30 Under 30 list, MIT Technology Review’s 35 Innovators Under 35, Popular Science Brilliant 10 of 2016, and most recently Business Insider’s Top 30 Young Leaders in Biopharma.

Cigall holds a BA in molecular and cellular biology from the University of California, Berkeley, and a PhD in cancer biology from the Stanford University School of Medicine.

 

Adam Koppel, MD, PhD

Managing Director, Bain Capital Life Sciences

Adam Koppel, MD, PhD

Managing Director, Bain Capital Life Sciences

Adam Koppel rejoined Bain Capital in 2016 as managing director of the Bain Capital Life Sciences Fund. He had initially joined Bain Capital Public Equity in 2003, where he was a leader within the healthcare sector until mid-2014. During the period mid-2014 to mid-2016, Adam was at Biogen, where he served as executive vice president of corporate development and chief strategy officer.

He sits on the board of directors of Solid Biosciences (NASDAQ: SLDB), Dicerna Pharmaceuticals (NASDAQ: DRNA), Trevena (NASDAQ: TRVN), Aptinyx Inc., and Foghorn Therapeutics. He is a former director of PTC Therapeutics (NASDAQ: PTCT).

Prior to joining Bain Capital in 2003, Adam was an associate principal at McKinsey & Company in New Jersey, where he served a variety of healthcare companies.

Adam sits on the Newton-Wellesley Hospital Board of Trustees, the Partners Healthcare Innovation Advisory Board, and the Society for Neuroscience Investment Committee.

Adam graduated magna cum laude from Harvard University with an AB and AM in history and science. He received his MD and PhD in neuroscience from the University of Pennsylvania School of Medicine. He also received an MBA from the Wharton School at the University of Pennsylvania, where he was a Palmer Scholar.

Michael Mendelsohn, MD

Chairman & Founder, Cardurion Pharmaceuticals

Michael Mendelsohn, MD

Chairman & Founder, Cardurion Pharmaceuticals

Michael Mendelsohn, MD, is a physician-scientist, research leader, and industry executive with broad experience in healthcare.

From 2010 through 2013, Michael served as the senior vice president and head of cardiovascular research at Merck Research Laboratories, with overall responsibility for the scientific direction of cardiovascular research from drug discovery through late development. He served as a venture partner at SV Life Sciences from 2014 to 2017. In 2016, he became executive chairman of Cardurion Pharmaceuticals, a cardiovascular biotechnology company.

Prior to joining Merck, Michael spent 1993 to 2010 at Tufts Medical Center and Tufts University School of Medicine, where he served as the first chief scientific officer and was founder and executive director of the Molecular Cardiology Research Institute. From 1988 to 1993, he served on the cardiovascular faculty of Brigham and Women’s Hospital and Harvard Medical School.

Michael completed an internal medicine internship and residency followed by a fellowship in cardiovascular medicine at Brigham and Women’s Hospital and Harvard Medical School. As a physician-scientist, Dr. Mendelsohn has studied signal transduction pathways regulating vascular and cardiac function and has published more than 150 papers.

Michael received his BA in chemistry and English from Amherst College, in Massachusetts, and his MD from Harvard Medical School.

Ian Smith

Chairman of the Board, Solid BioSciences and ViaCyte, Inc.

Ian Smith

Chairman of the Board, Solid BioSciences and ViaCyte, Inc.

Ian Smith is a biotechnology leader with more than 20 years of finance and operations experience. In addition to serving as an advisor and member of the Board of Directors of Foghorn Therapeutics, Ian serves as a senior advisor to Bain Capital Life Sciences, chair of the board of Solid Biosciences, gene therapy for DMD, executive chair of Viacyte Inc, cell therapy for diabetes, board member to AavantiBio, gene therapy for Freidricks Ataxia and provides advisory and consulting services to these and other biotechnology companies.

Prior to his current roles he was executive vice president and chief operating officer of Vertex Pharmaceuticals Inc. as well as chief financial officer between 2001 and 2019. Prior to 2001, Mr. Smith was a partner in the Life Science and Technology Practice of the accounting firm Ernst & Young LLP.

Ian received a B.A. with honors in accounting and finance from Manchester Metropolitan (UK).

José Baselga MD, PhD

In Memoriam

José Baselga MD, PhD

In Memoriam

José Baselga, MD, PhD, was a prolific researcher and visionary in the world of oncology. Over his 25+ years in the field, he conducted pivotal laboratory and clinical studies that led to the approval of trastuzumab, pertuzumab, and everolimus, among other therapies. He also contributed to more than 470 peer-reviewed publications with a longstanding interest in studying strategies to overcome mechanisms of resistance. His work as founding director of the Vall d’Hebron Institute of Oncology in Barcelona, Spain, helped build it to be one of the major oncology institutes of Europe. Throughout his career, he held executive leadership roles at AstraZeneca, Memorial Sloan Kettering Cancer Center, Harvard Medical School, Weill Cornell Medical College and Massachusetts General Hospital.

In addition to his work, José was involved in many industry-leading groups as a way to share his knowledge and insights with others. He held leadership positions with the American Association of Cancer Research (AACR), the European Society of Medical Oncology, and the American Society of Clinical Oncology at various points in his career. Additionally, José was an elected member of the National Academy of Medicine, the American Society of Clinical Investigation and the Association of American Physicians as well as a fellow of the AACR Academy. He dedicated efforts to publications as the founding editor-in-chief of Cancer Discovery, AACR’s flagship journal and editorial board member for Cancer Cell, Journal of Clinical Oncology and Clinical Cancer Research.

We had the honor of having José serve on our Board of Directors. All of us at Foghorn will continue our efforts guided by José’s fierce dedication to having a positive impact on patients.

Charles Sawyers, MD

Investigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; SAB Chair

Charles Sawyers, MD

Investigator, Howard Hughes Medical Institute Marie-Josée and Henry Kravis Chair in Human Oncology and Pathogenesis and Chairman, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center; SAB Chair

Charles L. Sawyers, MD, became a Howard Hughes Medical Institute investigator in 2002 and currently serves as the chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center.

Charles studies mechanisms of cancer drug resistance with an eye toward developing novel therapies. He co-discovered the anti-androgen drug enzalutamide, which was approved by the FDA in 2012 for treatment of advanced prostate cancer. Charles shared the 2009 Lasker-DeBakey Clinical Medical Research Award for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second-generation ABL inhibitor dasatinib to overcome imatinib resistance. He received the 2013 Breakthrough Prize in Life Sciences, the 2013 Taubman Prize for Excellence in Translational Medical Science, and the 2015 BBVA Knowledge Award in Biomedicine. Charles is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He is past president of the American Association for Cancer Research (AACR) and the American Society of Clinical Investigation, was appointed to the National Cancer Advisory Board by President Obama and has served on the board of directors of Novartis since 2013. He also serves as steering committee chair of AACR Project GENIE, an international consortium of cancer centers who share genomic and clinical data from patients treated at their respective clinical sites.

Charles holds a BA from Princeton University. He received his MD from Johns Hopkins University School of Medicine, followed by an internal medicine residency at UCSF.

Gerald Crabtree, MD

Founder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute

Gerald Crabtree, MD

Founder, Foghorn Therapeutics David Korn Professor, Stanford University Medical School Investigator, Howard Hughes Medical Institute

A founder of Ariad Pharmaceuticals and Amplyx Pharmaceuticals, Gerald Crabtree, MD, is the David Korn Professor at Stanford University and an investigator at the Howard Hughes Medical Institute. With more than 30 years of experience, Gerald has pioneered multiple key insights into mammalian developmental biology, including the discovery that one gene can produce different functional proteins by alternative splicing of mRNA transcripts.

In the 1980s and 1990s, his work with Stuart Schreiber to define the Ca2+/calcineurin/ NFAT signaling pathways resulted in the first understanding of how commonly used immunosuppressant drugs function. Later Gerald’s laboratory and others determined that these signals play essential roles in the development of the heart, immune, skeletonal, and nervous systems, even causing several phenotypes of Down syndrome. More recently, Gerald’s research into epigenetics, genetics, and chromatin remodeling complexes has a connection to several human neurologic diseases and cancers.

Gerald holds a B.S. in chemistry and mathematics from West Liberty State College, in West Virginia, and an M.D. from Temple University, in Philadelphia.

Tony Kouzarides, PhD, FMedSci, FRS

Professor of Cancer Biology at the University of Cambridge Director of the Milner Therapeutics Institute and Deputy Director of the Gurdon Institute

Tony Kouzarides, PhD, FMedSci, FRS

Professor of Cancer Biology at the University of Cambridge Director of the Milner Therapeutics Institute and Deputy Director of the Gurdon Institute

A prize-winning scientist, executive, professor, and founder, Tony Kouzarides, PhD, has made significant scientific discoveries and co-founded multiple companies including Abcam plc, Chroma Therapeutics, and STORM Therapeutics.

He currently serves as professor of cancer biology at the University of Cambridge, in the U.K., and as director of the university’s Milner Therapeutics Institute. He is also deputy director of the university’s Gurdon Institute, where he leads a research group focused on epigenetic modifications on chromatin, RNA, and DNA and their involvement in cancer. Tony’s work has demonstrated many links between epigenetic modifications and cancer. His laboratory was one of the first to identify a specific enzyme that can modify chromatin and to show that such genes are damaged in cancer cells.

Prior to his work at the Gurdon Institute, Tony completed postdoctoral work at the Medical Research Council Laboratory of Molecular Biology on the cancer-inducing potential of human cytomegalovirus. He followed his postdoctoral studies with research at New York University Medical Center, where he worked on the c-Fos onco-protein and characterized the leucine zipper dimerization interface.

Tony is the founder of a cancer charity in Spain called “Vencer el Cancer” and the founder of Cambridge Gravity, where he also serves as director. Tony is a member of the executive board of the Cambridge Cancer Centre and is on the scientific advisory board of two institutes on Spain: CRG in Barcelona and CABIMER in Seville.

Tony holds a BS in genetics from the University of Leeds and completed his PhD at the University of Cambridge.

David Schenkein, MD

General Partner, Co-leader, Google Ventures life science team Former CEO, Agios

David Schenkein, MD

General Partner, Co-leader, Google Ventures life science team Former CEO, Agios

David Schenkein, MD, is general partner and co-leader of Google Ventures’ life science team. He has been a hematologist and medical oncologist for more than 20 years and was the chief executive officer of Agios.

He currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, David was the senior vice president of clinical hematology/oncology at Genentech, where he was responsible for numerous successful oncology drug approvals and led the medical and scientific strategies for the BioOncology portfolio. While at Genentech, he also served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceuticals, overseeing the clinical development and worldwide approval of VELCADE®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkin’s lymphoma. He currently serves on the board of directors of bluebird bio and Denali Therapeutics.

David holds a BA in chemistry from Wesleyan University, in Connecticut, and an MD from the State University of New York Upstate Medical School.